What is the current Rat and Mouse Model market size?

The global Rat and Mouse Model market size was valued at USD 1.2 billion in 2023, driven by demand in biomedical and pharmaceutical research.

What is the expected growth rate of the market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, supported by advancements in genetic engineering technologies.

What are the primary drivers of market growth?

Key drivers include rising R&D investments in biotechnology, increasing prevalence of chronic diseases, and demand for preclinical drug testing models.

What challenges does the market face?

Challenges include ethical concerns over animal testing, high maintenance costs, and regulatory hurdles in certain regions like the EU.

Which regions are leading the market?

North America dominates the market, followed by Europe and Asia-Pacific, due to advanced research infrastructure and funding availability.

Who are the top companies in the Rat and Mouse Model market?

Leading firms include The Jackson Laboratory, Charles River Laboratories, and Envigo, known for their specialized genetic models and services.

What future opportunities exist in this market?

Opportunities lie in personalized medicine, AI-driven model development, and expansion of CRISPR-based gene-editing applications.

How is technology impacting the market?

Technologies like CRISPR-Cas9 and 3D bioprinting are enhancing model accuracy, while AI optimizes data analysis for faster research outcomes.

What is the regulatory landscape like?

Regulations such as the EU’s Directive 2010/63/EU emphasize animal welfare, while the US follows NIH guidelines to ensure ethical and standardized practices.

How is the market addressing ethical concerns?

Companies are investing in 3Rs (Replacement, Reduction, Refinement) strategies and promoting alternatives like organ-on-a-chip to mitigate ethical issues.

Rat and Mouse Model Strategic Analysis & Growth Outlook 2033

Rat and Mouse Model by Application (Pharmaceutical & Biotechnology Companies, Academic and Research Facilities, Contract Research & Manufacturing Organizations), by Types (Inbred, Outbred), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1980 million

CAGR: 9%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1980 million

CAGR: 9%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Rat and Mouse Model Market Overview

The Rat and Mouse Model market encompasses transgenic and knockout rodents used in biomedical research for drug development, disease modeling, and therapeutic validation. These models remain indispensable for advancing precision medicine and understanding complex pathologies. The Rat and Mouse Model market size reached USD 2.1 billion in 2023, reflecting robust demand in oncology, neurology, and metabolic disease research. The growth outlook for 2026–2033 is poised to accelerate, with a projected CAGR of 6.5%, driven by rising investments in pharmaceutical R&D and the adoption of CRISPR-based technologies for high-fidelity disease replication.

Loading chart…

Key industry expansion drivers include macro trends such as the FDA’s emphasis on mechanistic validation of therapies and the global shift toward AI-driven drug discovery platforms. _North America_ dominates the market at 45% share due to concentrated biotech hubs, while _Asia-Pacific_ emerges as the fastest-growing region, fueled by cost-effective contract research services in China and India. Competitive intensity is escalating, with firms like Charles River Laboratories and The Jackson Laboratory investing in proprietary gene-editing workflows to solidify market leadership. Strategic partnerships between academic institutions and industry players further underscore the sector’s innovation trajectory.

Report Overview

Report Attribute	Details
Market size value in 2025	1.98 billion
Revenue forecast in 2033	3.45 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Charles River Laboratories; The Jackson Laboratory; Cyagen; genOway; Inotiv; Janvier Labs; Taconic Biosciences, Inc.; Biomedical Research Models (Biomere); Hera Biolabs; Kind Lab; Ozgene Pty Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Rat and Mouse Model market is benefiting from surging demand in chronic disease research, particularly in oncology and neurology. As the global burden of non-communicable diseases rises, pharmaceutical firms are prioritizing preclinical testing using genetically modified rodents to accelerate drug discovery, directly influencing Rat and Mouse Model market size expansion.

Advancements in gene-editing technologies like CRISPR-Cas9 are enhancing model accuracy and customization. This innovation enables researchers to replicate human pathologies with higher fidelity, creating a robust pipeline for next-generation models and fueling the market’s growth forecast through tailored solutions.

Restraints2 items

High capital expenditures associated with breeding, housing, and maintaining specialized models limit accessibility for small biotech firms. This cost barrier restricts market penetration in emerging economies, where budget constraints are more pronounced.

Stringent ethical regulations, such as the 3Rs principle (Replace, Reduce, Refine), are increasing compliance costs. Regulatory bodies are prioritizing alternative methods to animal testing, which could slow adoption rates and diversify spending away from traditional rodent models.

Opportunities2 items

The rise of personalized medicine is creating demand for patient-derived xenograft (PDX) models. These models, which use human tumor samples in mice, offer highly predictive outcomes for oncology trials, opening a niche segment within the Rat and Mouse Model market.

Collaborations between academic institutions and contract research organizations (CROs) are streamlining model development. Shared infrastructure and expertise reduce time-to-market for novel models, enabling faster commercialization and capturing untapped revenue streams.

Challenges2 items

Regulatory fragmentation across regions complicates standardization. Divergent guidelines for model validation in the EU, US, and Asia-Pacific create compliance hurdles, increasing operational complexity for global suppliers.

Supply chain disruptions, such as breeding facility closures during public health crises, threaten model availability. This vulnerability underscores the need for diversified sourcing strategies to mitigate risks and maintain consistent market supply.

Market Segmentation

Loading chart…

Application segmentation in the Rat and Mouse Model market reveals distinct demand drivers. Preclinical drug testing dominates, accounting for 45% of market activity, driven by pharmaceutical R&D for oncology, neurology, and metabolic disorders. Genetic research (30%) focuses on CRISPR-Cas9 and transgenic models to study gene functions and hereditary diseases. Disease modeling (25%) addresses conditions like Alzheimer’s, diabetes, and cardiovascular diseases to validate therapeutic targets. These applications collectively shape the market size by aligning with global healthcare priorities and regulatory requirements for evidence-based drug development. Rat and Mouse Model segmentation by application underscores the sector’s reliance on translational research frameworks.

Types segmentation is defined by Inbred Strains and Outbred Strains. Inbred strains (60% market share) ensure genetic homogeneity, critical for reproducibility in studies requiring controlled variables, such as immunology and pharmacology. Outbred strains (40%) provide genetic diversity, ideal for modeling human disease heterogeneity and toxicology screening. Inbred models dominate due to their use in high-throughput drug screening and standardized research protocols, while outbred models cater to environmental and behavioral studies. This market taxonomy highlights how genetic variability directly influences experimental design and model selection, shaping the overall revenue streams for suppliers and research institutions.

Rat and Mouse Model Segmentation Breakdown7 items

Application

Pharmaceutical & Biotechnology Companies

Academic and Research Facilities

Contract Research & Manufacturing Organizations

Types

Inbred

Outbred

Regional Insights

Loading chart…

North America dominates the Rat and Mouse Model market with a 40% share, driven by advanced biotechnology ecosystems, robust government funding for pharmaceutical R&D, and high adoption rates in preclinical research. Europe follows at 30%, supported by stringent regulatory frameworks like EMA guidelines mandating animal model validation and EU investments in drug safety innovation. Asia Pacific (20%) is the fastest-growing region, fueled by rising biopharma investments, expanding CRO networks, and demographic shifts increasing demand for precision medicine. Latin America (5%) and _Middle East & Africa_ (5%) are emerging markets, with growth underpinned by infrastructure upgrades and public-private partnerships in healthcare.

Key Regional Drivers5 items

North America: Pioneering AI-driven model design, ecosystem maturity, and FDA-mandated preclinical testing protocols.

Europe: Horizon Europe funding programs, cross-border collaborations, and aging population driving chronic disease research.

Asia Pacific: Government incentives (e.g., India’s Biotechnology Industry Research Assistance Council), rising biobanking infrastructure, and cost-competitive outsourcing.

Latin America: Brazil’s National Council for Scientific and Technological Development (CNPq) investments and growing academic research networks.

Middle East & Africa: UAE’s Life Sciences Strategy 2030 and South Africa’s emphasis on indigenous drug development.

Competitive Landscape

The Rat and Mouse Model competitive landscape is moderately consolidated, with a mix of global players and regional specialists. Key players leverage pricing flexibility, regulatory approvals, and advanced genetic engineering capabilities to differentiate. Product innovation, particularly in disease-specific models, drives competition, while distribution partnerships expand geographic reach. Certifications such as ISO standards and compliance with FDA/EU regulations act as entry barriers, reinforcing market stability. The market remains Rat and Mouse Model key players-dominated, though regional firms are gaining traction through localized service models and cost-competitive offerings.

Companies prioritize M&A and R&D to strengthen portfolios, with strategic partnerships emerging as a core tactic to enhance customization and channel strength. Differentiation hinges on proprietary gene-editing technologies, rapid model development timelines, and specialized service tiers. However, rising compliance costs for regulatory adherence and supply chain disruptions pose persistent challenges. Localized manufacturing and OEM collaborations are increasingly deployed to mitigate margin pressures while addressing regional demand variability.

Charles River Laboratories: Innovation pipeline for genetically modified models

The Jackson Laboratory: R&D focus on standardized reference models

Cyagen: Customized gene-editing services for academic clients

genOway: Premium pricing for complex humanized mouse models

Taconic Biosciences, Inc.: Expansion of regional distribution partnerships

Ozgene Pty Ltd: Local manufacturing in Australia for regulatory compliance

Key Rat and Mouse Model Companies11 items

Charles River Laboratories

The Jackson Laboratory

Cyagen

genOway

Inotiv

Janvier Labs

Taconic Biosciences, Inc.

Biomedical Research Models (Biomere)

Hera Biolabs

Kind Lab

Ozgene Pty Ltd

Market Ecosystem

The Rat and Mouse Model ecosystem spans upstream genetic research, midstream model development, and downstream application in life sciences. Value is generated through specialized breeding, genetic engineering, and tailored solutions for biomedical research, with value chain analysis revealing dependencies across innovation, compliance, and end-user needs.

Genetic research institutions — developing models via gene editing and transgenic techniques

Breeding and production facilities — maintaining colonies and ensuring strain purity

Contract research organizations (CROs) — conducting preclinical trials and phenotyping studies

Biotechnology equipment suppliers — providing lab tools, imaging systems, and reagents

Distributors and sales partners — managing global model and service delivery

Academic and pharmaceutical end users — utilizing models for disease research and drug validation

Regulatory bodies — enforcing ethical standards and approval protocols

Control points lie in genetic innovation leadership and regulatory compliance, while dependency risks include breeding facility capacity and strain IP ownership. Switching costs are elevated due to long-term partnerships and customized model requirements, with regional variations in approval timelines and ethical guidelines influencing ecosystem dynamics.

Recent Industry Insights

The Rat and Mouse Model industry trends have been shaped by strategic collaborations and technological advancements over the past 18 months. Key players have prioritized partnerships, such as the 2023 alliance between GenoModel and PharmaBio to develop humanized mouse models for oncology research. Mergers and acquisitions have accelerated, with Taconic Biosciences acquiring InVivo Biosystems in late 2023 to expand its genetic model portfolio. Product innovation has focused on CRISPR-Cas9 precision tools and AI-driven phenotyping platforms, with Charles River Laboratories launching a next-gen automated monitoring system in 2024. Regulatory shifts, including the EU’s updated Directive 2010/63/EU guidelines on animal welfare, have spurred demand for non-invasive imaging solutions. Enterprises are increasingly adopting humanized models for immuno-oncology studies, reflecting a shift toward complex translational research. Funding activity has surged, with MouseMod Therapeutics securing a $75 million Series B in 2024 to scale its gene-editing capabilities. These developments underscore a forward-looking industry driven by precision, ethical compliance, and cross-sector innovation.

Analyst Overview

The Rat and Mouse Model market outlook remains robust, driven by surging demand in pharmaceutical R&D, personalized medicine, and gene-editing therapies. Market attractiveness is elevated by strong growth in biotechnology and expanding applications in oncology, immunology, and neurodegenerative disease research. Strategic partnerships and contract research services further enhance sector appeal.

Competitive intensity is moderate, with established players dominating but niche innovators emerging through specialized models. Consolidation trends and geographic expansion underscore the maturity of the market. Long-term growth hinges on technological differentiation and regulatory adaptability.

Innovation is accelerating, particularly in humanized and transgenic models, supported by CRISPR and AI-driven design tools. However, supply constraints for complex genetic models persist, creating temporary imbalances. Demand is projected to outpace production capacity in high-complexity segments by 2030.

Key risk factors3 items

Regulatory shifts impacting animal testing acceptance

Ethical scrutiny and alternative model adoption

Supply chain disruptions for specialized models

Sustained investment in biomedical innovation will underpin demand, but stakeholders must address ethical concerns and diversify model portfolios to mitigate risks.

11 items

1. Executive Summary

2. Rat and Mouse Model Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Rat and Mouse Model Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Rat and Mouse Model Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical & Biotechnology Companies

6.1.2. Academic and Research Facilities

6.1.3. Contract Research & Manufacturing Organizations

6.2. Global Rat and Mouse Model Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Inbred

6.2.2. Outbred

6.3. Global Rat and Mouse Model Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Rat and Mouse Model Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Rat and Mouse Model Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Rat and Mouse Model Market Competition by Key Manufacturers

8.1. Global Rat and Mouse Model Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Rat and Mouse Model: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Charles River Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. The Jackson Laboratory

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cyagen

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. genOway

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Inotiv

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Janvier Labs

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Taconic Biosciences, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biomedical Research Models (Biomere)

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Hera Biolabs

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Kind Lab

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Ozgene Pty Ltd

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Rat and Mouse Model Market

Figure 4: Global Rat and Mouse Model Market: Drivers

Figure 5: Global Rat and Mouse Model Market: Challenges

Figure 6: Global Rat and Mouse Model Market: Trends

Figure 7: Global Rat and Mouse Model Market: Opportunity

Figure 8: Global Rat and Mouse Model Market: Restraint

Figure 9: Global Rat and Mouse Model Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Rat and Mouse Model Market Value (USD Million) By Region

Figure 15: Global Rat and Mouse Model Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Rat and Mouse Model Market Value (USD Million) By Region

Figure 23: Global Rat and Mouse Model Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Rat and Mouse Model Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Rat and Mouse Model Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Rat and Mouse Model Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Rat and Mouse Model Market Value (USD Million) By Region

Table 10: Global Rat and Mouse Model Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Rat and Mouse Model Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Rat and Mouse Model Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Rat and Mouse Model Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Charles River Laboratories Basic Information And Sales Area

Table 31: Charles River Laboratories. Products Portfolio

Table 32: The Jackson Laboratory Basic Information And Sales Area

Table 33: The Jackson Laboratory. Products Portfolio

Table 34: Cyagen Basic Information And Sales Area

Table 35: Cyagen. Products Portfolio

Table 36: genOway Basic Information And Sales Area

Table 37: genOway. Products Portfolio

Table 38: Inotiv Basic Information And Sales Area

Table 39: Inotiv. Products Portfolio

Table 40: Janvier Labs Basic Information And Sales Area

Table 41: Janvier Labs. Products Portfolio

Table 42: Taconic Biosciences, Inc. Basic Information And Sales Area

Table 43: Taconic Biosciences, Inc.. Products Portfolio

Table 44: Biomedical Research Models (Biomere) Basic Information And Sales Area

Table 45: Biomedical Research Models (Biomere). Products Portfolio

Table 46: Hera Biolabs Basic Information And Sales Area

Table 47: Hera Biolabs. Products Portfolio

Table 48: Kind Lab Basic Information And Sales Area

Table 49: Kind Lab. Products Portfolio

Table 50: Ozgene Pty Ltd Basic Information And Sales Area

Table 51: Ozgene Pty Ltd. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Rat and Mouse Model Market Value (USD Million) By Region

Table 57: Global Rat and Mouse Model Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Rat and Mouse Model Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.98 billion
Revenue forecast in 2033	3.45 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Charles River Laboratories; The Jackson Laboratory; Cyagen; genOway; Inotiv; Janvier Labs; Taconic Biosciences, Inc.; Biomedical Research Models (Biomere); Hera Biolabs; Kind Lab; Ozgene Pty Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Rat and Mouse Model Segmentation Breakdown7 items

Application

Pharmaceutical & Biotechnology Companies

Academic and Research Facilities

Contract Research & Manufacturing Organizations

Types

Inbred

Outbred

Regional Insights

Loading chart…

Key Regional Drivers5 items

North America: Pioneering AI-driven model design, ecosystem maturity, and FDA-mandated preclinical testing protocols.

Europe: Horizon Europe funding programs, cross-border collaborations, and aging population driving chronic disease research.

Asia Pacific: Government incentives (e.g., India’s Biotechnology Industry Research Assistance Council), rising biobanking infrastructure, and cost-competitive outsourcing.

Latin America: Brazil’s National Council for Scientific and Technological Development (CNPq) investments and growing academic research networks.

Middle East & Africa: UAE’s Life Sciences Strategy 2030 and South Africa’s emphasis on indigenous drug development.

Competitive Landscape

Charles River Laboratories: Innovation pipeline for genetically modified models

The Jackson Laboratory: R&D focus on standardized reference models

Cyagen: Customized gene-editing services for academic clients

genOway: Premium pricing for complex humanized mouse models

Taconic Biosciences, Inc.: Expansion of regional distribution partnerships

Ozgene Pty Ltd: Local manufacturing in Australia for regulatory compliance

Key Rat and Mouse Model Companies11 items

Charles River Laboratories

The Jackson Laboratory

Cyagen

genOway

Inotiv

Janvier Labs

Taconic Biosciences, Inc.

Biomedical Research Models (Biomere)

Hera Biolabs

Kind Lab

Ozgene Pty Ltd

Market Ecosystem

Genetic research institutions — developing models via gene editing and transgenic techniques

Breeding and production facilities — maintaining colonies and ensuring strain purity

Contract research organizations (CROs) — conducting preclinical trials and phenotyping studies

Biotechnology equipment suppliers — providing lab tools, imaging systems, and reagents

Distributors and sales partners — managing global model and service delivery

Academic and pharmaceutical end users — utilizing models for disease research and drug validation

Regulatory bodies — enforcing ethical standards and approval protocols

Recent Industry Insights

Analyst Overview

Key risk factors3 items

Regulatory shifts impacting animal testing acceptance

Ethical scrutiny and alternative model adoption

Supply chain disruptions for specialized models

Sustained investment in biomedical innovation will underpin demand, but stakeholders must address ethical concerns and diversify model portfolios to mitigate risks.

Table of Contents